Where can I learn more about this study?
You can find more information about this study on the websites listed below. If
more information about the study results is available, it can also be found here.
> www.clinicaltrials.gov. Once you are on the website, type “NCT03608358”
into the search box and click “Search”.
www.AstraZenecaClinicalTrials.com. Once you are on the website, type
>
“D1683C00008” into the search box, and click “Find a Study”.
Full Study Title: A Multicenter, Randomized, Double-Blind, Double-Dummy,
Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and
Efficacy of Therapy with Dapagliflozin Added to Saxagliptin in Combination
with Metformin Compared to Therapy with Placebo added to Saxagliptin in
Combination with Metformin in Asian Subjects with Type 2 Diabetes Who Have
Inadequate Glycemic Control on Metformin and Saxagliptin (DS Navigation)
AstraZeneca AB Protocol Number: D1683C00008
National Clinical Trials number: NCT03608358
AstraZeneca AB sponsored this study and has its headquarters in Södertälje,
Sweden.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you!
Participants in clinical studies belong to a large community of
people who take part in clinical research around the world.
They help researchers answer important health questions and
find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused
on educating and informing the public about clinical research participation. CISCRP is not involved in recruiting
participants for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2021_04_20
10 | Clinical Study Results